American Oriental Bioengineering Inc (AOBI)

Currency in USD
0.0005
0.0000(0.00%)
Closed·

AOBI Financial Summary

Key Ratios

P/E Ratio0
Price/Book0
Debt / Equity32.7%
Return on Equity-28.22%
Dividend Yield0.00%
EBITDA-42.94M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2003
31/12
2004
31/12
2005
31/12
2006
31/12
2007
31/12
2008
31/12
2009
31/12
2010
31/12
2011
31/12
2012
31/12
* In Millions of USD (except for per share items)

Earnings

Latest Release
Nov 18, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What was American Oriental Bioengineering's net income for the latest quarter?

American Oriental Bioengineering's net income for the latest quarter was -21.18.

How did American Oriental Bioengineering's performance compare year-over-year in the latest quarter?

The company's revenue moved from 20.22 in the previous quarter to 17.94 in the latest quarter, and net income moved from -12.84 to -21.18 compared to the previous quarter.

What is American Oriental Bioengineering's net profit margin on a TTM basis?

American Oriental Bioengineering's trailing twelve months (TTM) net profit margin is -41.15%.

How does American Oriental Bioengineering's debt to equity ratio compare to industry standards?

American Oriental Bioengineering's total debt-to-equity ratio is 32.70%.

What is American Oriental Bioengineering's return on investment on a TTM basis?

American Oriental Bioengineering's trailing twelve months (TTM) return on investment (ROI) is -28.22%.

Did American Oriental Bioengineering gain or lose cash last quarter?

In the latest quarter, American Oriental Bioengineering's net change in cash was -3.77 million.

What were American Oriental Bioengineering's total assets and liabilities in the latest quarter?

As of the latest quarter, American Oriental Bioengineering reported total assets of 427.62 million and total liabilities of 126.31 million.

How has American Oriental Bioengineering's total revenue grown this year?

American Oriental Bioengineering's total revenue was 20.22 in the previous quarter and 17.94 in the latest quarter.

What was American Oriental Bioengineering's revenue per share for the latest quarter?

American Oriental Bioengineering's revenue per share for the latest quarter was 43.82.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.